Cabozantinib is approved under the brand ... The drug is approved for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, and for adult and ...

French drugmaker Ipsen’s Cabometyx (cabozantinib ... use in England and Wales for previously treated advanced hepatocellular carcinoma (HCC), it has been announced. Those adult patients who ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib ... for the treatment of hepatocellular carcinoma. The drug is approved ...

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC ... and Ipsen’s Cabometyx (cabozantinib). Opdivo’s US approval for ...

according to a press release from the Dana-Farber Cancer Institute. The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with ...

This retrospective analysis included 102 patients with advanced RCC treated with either cabozantinib + nivolumab or lenvatinib + pembrolizumab as first-line therapy at Tokyo Women's Medical University ...

The oral presentation will highlight the first safety and efficacy data for the ARC-20 expansion cohort evaluating the HIF-2a inhibitor casdatifan plus cabozantinib, an anti-vascular endothelial ...